Cargando…

Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux

INTRODUCTION: Kidney transplant recipients and patients on hemodialysis are immunocompromised populations, prioritized for COVID 19 vaccination, but excluded from vaccine trials. Data are lacking regarding humoral response to COVID vaccination in immunocompromised patients. DESCRIPTION: We investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Touré, F., Danthu, C., Hantz, S., Duval, M., El Ouafi, Z., Allot, V., Bocquentin, F., Rerolle, J.P., Alain, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435332/
http://dx.doi.org/10.1016/j.nephro.2021.07.137
_version_ 1783751771130167296
author Touré, F.
Danthu, C.
Hantz, S.
Duval, M.
El Ouafi, Z.
Allot, V.
Bocquentin, F.
Rerolle, J.P.
Alain, S.
author_facet Touré, F.
Danthu, C.
Hantz, S.
Duval, M.
El Ouafi, Z.
Allot, V.
Bocquentin, F.
Rerolle, J.P.
Alain, S.
author_sort Touré, F.
collection PubMed
description INTRODUCTION: Kidney transplant recipients and patients on hemodialysis are immunocompromised populations, prioritized for COVID 19 vaccination, but excluded from vaccine trials. Data are lacking regarding humoral response to COVID vaccination in immunocompromised patients. DESCRIPTION: We investigated early serological response after COVID 19 vaccination with Pfizer/BioNTech (BNT162b2) mRNA vaccine in groups of patients undergoing hemodialysis (n = 78), kidney transplant recipients (n = 74), and in healthy controls. Antibody titers against SARS-CoV-2 at days 0, 14, 28, 36 and 58 after the first injection were measured. METHODS: Antibody titers against SARS-CoV-2 at days 0, 14, 28, 36 and 58 after the first injection were measured. RESULTS: A total of 74 transplant recipients (mean age 64.8 ± 11.5 years, 38.9% women), 78 hemodialysis patients (mean age 73.5 ± 12.8 years, 40.2% women) and 7 healthy controls (mean age 51.6 ± 6.8, 42% women) were included. In controls, antibodies were detected at a significant level (> 13 AU/ml) at day 14 post-injection, and increased progressively, to peak at day 36 (median 1372 AU/mL [IQR 490.2-4540.5]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (median 4.0 AU/mL [IQR: 1.85-12.2] at day 14; 6.6 AU/mL [IQR 2.1-19.0] at day 36; 276 AU/mL [IQR 83.4-526.0] at day 58). A significant antibody level was detected in only 3 kidney transplant recipients at day 36. In hemodialysis patients, age, serum albumin and Kt/V were positively correlated with serological response (P < 0.043 and P < 0.019 respectively); non responders to HBV vaccine had the lowest titers of anti-SARS-CovV-2 antibodies (Fig. 1). CONCLUSION: Our results suggest that the post-vaccine humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, while it is lowered by the uremic condition in patients undergoing hemodialysis.
format Online
Article
Text
id pubmed-8435332
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Masson SAS
record_format MEDLINE/PubMed
spelling pubmed-84353322021-09-13 Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux Touré, F. Danthu, C. Hantz, S. Duval, M. El Ouafi, Z. Allot, V. Bocquentin, F. Rerolle, J.P. Alain, S. Nephrol Ther Pc-04 INTRODUCTION: Kidney transplant recipients and patients on hemodialysis are immunocompromised populations, prioritized for COVID 19 vaccination, but excluded from vaccine trials. Data are lacking regarding humoral response to COVID vaccination in immunocompromised patients. DESCRIPTION: We investigated early serological response after COVID 19 vaccination with Pfizer/BioNTech (BNT162b2) mRNA vaccine in groups of patients undergoing hemodialysis (n = 78), kidney transplant recipients (n = 74), and in healthy controls. Antibody titers against SARS-CoV-2 at days 0, 14, 28, 36 and 58 after the first injection were measured. METHODS: Antibody titers against SARS-CoV-2 at days 0, 14, 28, 36 and 58 after the first injection were measured. RESULTS: A total of 74 transplant recipients (mean age 64.8 ± 11.5 years, 38.9% women), 78 hemodialysis patients (mean age 73.5 ± 12.8 years, 40.2% women) and 7 healthy controls (mean age 51.6 ± 6.8, 42% women) were included. In controls, antibodies were detected at a significant level (> 13 AU/ml) at day 14 post-injection, and increased progressively, to peak at day 36 (median 1372 AU/mL [IQR 490.2-4540.5]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (median 4.0 AU/mL [IQR: 1.85-12.2] at day 14; 6.6 AU/mL [IQR 2.1-19.0] at day 36; 276 AU/mL [IQR 83.4-526.0] at day 58). A significant antibody level was detected in only 3 kidney transplant recipients at day 36. In hemodialysis patients, age, serum albumin and Kt/V were positively correlated with serological response (P < 0.043 and P < 0.019 respectively); non responders to HBV vaccine had the lowest titers of anti-SARS-CovV-2 antibodies (Fig. 1). CONCLUSION: Our results suggest that the post-vaccine humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, while it is lowered by the uremic condition in patients undergoing hemodialysis. Published by Elsevier Masson SAS 2021-09 2021-09-12 /pmc/articles/PMC8435332/ http://dx.doi.org/10.1016/j.nephro.2021.07.137 Text en Copyright © 2021 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Pc-04
Touré, F.
Danthu, C.
Hantz, S.
Duval, M.
El Ouafi, Z.
Allot, V.
Bocquentin, F.
Rerolle, J.P.
Alain, S.
Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux
title Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux
title_full Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux
title_fullStr Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux
title_full_unstemmed Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux
title_short Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux
title_sort cinétique de la réponse humorale après administration d’un vaccin sars-cov-2 mrna dans une cohorte de patients transplantés et greffés rénaux
topic Pc-04
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435332/
http://dx.doi.org/10.1016/j.nephro.2021.07.137
work_keys_str_mv AT touref cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux
AT danthuc cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux
AT hantzs cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux
AT duvalm cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux
AT elouafiz cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux
AT allotv cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux
AT bocquentinf cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux
AT rerollejp cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux
AT alains cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux